Member Info for Soupdragon78

Even without NDA's in place, we will not hear whether they are talking to anyone or not. Even preliminary contact is usually tightly guarded in pharma.

Anyone hoping for the company to say they are in talks with anyone in particular is deluded.

As jiving says nothing will come before the additional studies are done and that depends on the availability of donors. We know that last time they had to wait 6 months longer than expected to get the donor organ and this time they need 3.

Ok FX, so you're saying that despite Dan leaving NFX in June 2020 he somehow is responsible for the terms and conditions of the deal that was finalised and signed in September 2021. Makes sense.

FX, Dan didn't sell anything relating to NXP001. His side was related to the lipid based work on OXL001 which has nothing to do with NFX.

As you will remember Dan left NFX in June 2020 and the Oxilio deal was signed a year and a half later in September 2021.

With the average phase 2 clinical cost £13m I doubt think that 850k raise is going to get them far with their lead asset.

I think they would take it given the chance. Plus I think it would be beneficial to NFX in the short term. Agreed it isn't their lead asset, their priority has always been oxl001.

For Oxilio, it would save them future royalty payments, so nets off in the long run.

For NFX, the milestone payments are still some way away so don't help the need for cash in the short term. And royalty payments are years away, so not really a consideration.

If Oxilio paid 500-800k for nxp001, I wouldn't have problems with that. Gives some cash to get 002 and 004 to license where the real value sits.

If they offered a sum to take nxp001 in full and that sum allowed NFX to get 002 and 004 through to outlicensing then what would be your thoughts?

I like how Oxilio have fudged their chart on the investors page of their website so as not to show stagnation.

They indicate they have raised 1.2m although they’re only reporting 850k to companies house.

Wonder what they’ll spend it on?

Still keeps their valuation at £254m which is a constant source of hilarity.

So Oxilio have just raised £850k, they must have something to do.

Lol! Good to see you're getting your excuses in early NFTs.

Gone from something will definitely happen in July, to 'oh its an invoicing thing' to now maybe something else means it won't happen like I was so confident about.

Could Inhaled Therapies be the Future for Fibrosing Lung Conditions?

https://www.breathingmatters.co.uk/about/could-inhaled-therapies-be-the-future-for-fibrosing-lung-conditions/

Chill the beans Mulder, obviously nothing for you to worry your pretty little head about then is there.

Poster who said NXP004 couldn't possibly be based on Lynparza / Olaparib and that no auditor would go near the company, seems to think he's got something worth saying.

Wouldn’t surprise me if he fully sold off nxp001 in the short term. The milestones would be some way off in the future, so may be worth the cash in the short term to get 002 over the line.

Lucky Dan ;-)

I understand Fx, but at the time of the deal he wasn’t involved with NFX so I don’t see why he would have done us any favours. You don’t expect a footballer to not score against a former team.

At the end of the day it was Brindley who signed off the deal, she didn’t have to do so. My interpretation is that she saw nxp001 as not of any significance so just wanted rid.

Corry, people seem to be forgetting that an insti just took out warrants for 4.5% of the company.

They wouldn’t have done so if they thought the company was going to dilute them within a couple of months.

They know the cash runway.

Dan wasn’t with NfX when that was finalised, it was Anne and Alastairs deal. Dans subsequent selling of his consultancy to Oxilio was solely related to oxl001 and not NFX side.

Hear you FX, but Oxilio was a straight full-on outlicense.

Collaboration would keep an element of NFX input into the next steps and process.

Theres plenty of ways to skin a cat.

"My preference would be that we would find some collaborative development partner and that a lot of the sort of knowledge that sits within the business, the network that it has in terms of NXP002 can go forward and be a part of building value and some retained value in progressing that asset value chain so that would be my preferred path."